RACE 7 AWS Trial Criteria for Wait-and-See Approach
I cannot provide the specific criteria for a wait-and-see approach in the RACE 7 Acute Workflow Implementation (AWS) trial because none of the provided evidence documents contain information about this trial.
What the Evidence Actually Contains
The evidence provided relates to entirely different clinical topics:
- Acute ischemic stroke management 1, 2 - These guidelines discuss stroke intervention trials including NINDS rt-PA and other stroke studies, but make no mention of RACE 7 AWS
- Alcohol withdrawal syndrome (AWS) 3, 4, 5, 6 - Multiple sources discuss "AWS" as an acronym for Alcohol Withdrawal Syndrome, not the RACE 7 trial
- Valvular heart disease 1
- Mantle cell lymphoma 1
- Sinusitis 1
- General clinical trial methodology 7, 8, 9
Critical Clarification Needed
The RACE 7 AWS trial appears to be a stroke trial (based on the context mentioning "minor or improving symptoms" which is consistent with acute stroke presentations), but the specific inclusion criteria, wait-and-see approach parameters, and workflow implementation details are not present in any of the provided evidence sources.
To answer your question accurately, I would need access to:
- The actual RACE 7 AWS trial protocol or publication
- Guidelines or evidence specifically referencing this trial's methodology
- Documentation of the trial's patient selection criteria and observation protocols
The evidence about stroke management 1 does mention that "approximately one third of patients who are not treated with intravenous rtPA because of mild or rapidly improving stroke symptoms on hospital arrival have a poor final stroke outcome," but this is general stroke management guidance, not RACE 7 AWS trial-specific criteria.